Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369727 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
A Phase 1 study, sponsored by Moberg Pharma AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT06369727 is a Phase 1 study that has completed, run by Moberg Pharma AB. The registered enrollment target is 250 participants.
The verdict
NCT06369727, a Phase 1 study, has completed, sponsored by Moberg Pharma AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential
Interventions
- DRUG MOB015B
- DRUG MOB015B vehicle
- DRUG Negative irritant solution of 0.9% saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2017-10-15 |
| Est. Completion | 2018-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06369727
The ClinicalTrials.gov registry entry for NCT06369727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Moberg Pharma AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MOB015B is the first listed.
NCT06369727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06369727 about?
NCT06369727 is a clinical study titled "Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design". A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential
What is the current status of trial NCT06369727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2017-10-15. Estimated completion is 2018-02-15.
What interventions are being tested in trial NCT06369727?
The interventions under investigation include: MOB015B (DRUG), MOB015B vehicle (DRUG), Negative irritant solution of 0.9% saline (DRUG).
Who is sponsoring clinical trial NCT06369727?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.